WO2014186623A3 - Methods and compositions for the treatment of a chagas disease - Google Patents

Methods and compositions for the treatment of a chagas disease Download PDF

Info

Publication number
WO2014186623A3
WO2014186623A3 PCT/US2014/038268 US2014038268W WO2014186623A3 WO 2014186623 A3 WO2014186623 A3 WO 2014186623A3 US 2014038268 W US2014038268 W US 2014038268W WO 2014186623 A3 WO2014186623 A3 WO 2014186623A3
Authority
WO
WIPO (PCT)
Prior art keywords
chagas disease
inhibitor
compositions
methods
benznidazole
Prior art date
Application number
PCT/US2014/038268
Other languages
French (fr)
Other versions
WO2014186623A2 (en
Inventor
Jeffrey James ROIX
Saurabh Saha
Original Assignee
Biomed Valley Discoveries
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biomed Valley Discoveries filed Critical Biomed Valley Discoveries
Publication of WO2014186623A2 publication Critical patent/WO2014186623A2/en
Publication of WO2014186623A3 publication Critical patent/WO2014186623A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4168—1,3-Diazoles having a nitrogen attached in position 2, e.g. clonidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention provides, inter alia, methods for treating or ameliorating the effects of a Chagas disease. The methods include administering to a subject in need thereof an effective amount of a first active agent selected from the group consisting of a histamine-H1-receptor antagonist, a selective neutrophil elastase inhibitor, an ergot alkaloid derivative, an inhibitor of 3 β-hydroxysteroid dehydrogenase, a reversible acetylcholinesterase inhibitor, a protease inhibitor, an aldosterone antagonist, a naphthoquinone, and combinations thereof, and a second active agent, which is benznidazole. Also provided are compositions for treating or ameliorating the effects of a Chagas disease. The compositions include azelastine and benznidazole in amounts effective to treat or ameliorate the effect of a Chagas disease and a pharmaceutically acceptable carrier.
PCT/US2014/038268 2013-05-17 2014-05-15 Methods and compositions for the treatment of a chagas disease WO2014186623A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361824406P 2013-05-17 2013-05-17
US61/824,406 2013-05-17

Publications (2)

Publication Number Publication Date
WO2014186623A2 WO2014186623A2 (en) 2014-11-20
WO2014186623A3 true WO2014186623A3 (en) 2015-03-05

Family

ID=51899011

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2014/038268 WO2014186623A2 (en) 2013-05-17 2014-05-15 Methods and compositions for the treatment of a chagas disease

Country Status (1)

Country Link
WO (1) WO2014186623A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016209490B2 (en) 2015-01-20 2020-09-03 Xoc Pharmaceuticals, Inc. Isoergoline compounds and uses thereof
WO2016118541A1 (en) 2015-01-20 2016-07-28 Xoc Pharmaceuticals, Inc Ergoline compounds and uses thereof
CN104745649B (en) * 2015-02-28 2018-03-09 苏州汉酶生物技术有限公司 A kind of biological preparation method of fosamprenavir intermediate
WO2018076019A1 (en) * 2016-10-21 2018-04-26 Far Biotech, Inc. Ergot derivative compounds and their use in african sleeping sickness and related disease
CA3064274A1 (en) 2017-06-01 2018-12-06 Xoc Pharmaceuticals, Inc. Ergoline derivatives for use in medicine
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
EP3955918A1 (en) 2019-04-17 2022-02-23 COMPASS Pathfinder Limited Methods of treating neurocognitive disorders, chronic pain and reducing inflammation

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090017021A1 (en) * 2004-07-18 2009-01-15 Coley Pharmaceutical Group, Ltd. Methods and compositions for inducing innate immune responses
US20120308644A1 (en) * 2004-06-17 2012-12-06 Philip James Bromley Compositions for mucosal delivery of agents
WO2013059898A1 (en) * 2011-10-24 2013-05-02 Universidade Federal De Ouro Preto - Ufop Pharmaceutical compositions containing sesquiterpene lactones belonging to the class of furan heliangolides for the treatment of parasitic infections and tumours

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120308644A1 (en) * 2004-06-17 2012-12-06 Philip James Bromley Compositions for mucosal delivery of agents
US20090017021A1 (en) * 2004-07-18 2009-01-15 Coley Pharmaceutical Group, Ltd. Methods and compositions for inducing innate immune responses
WO2013059898A1 (en) * 2011-10-24 2013-05-02 Universidade Federal De Ouro Preto - Ufop Pharmaceutical compositions containing sesquiterpene lactones belonging to the class of furan heliangolides for the treatment of parasitic infections and tumours

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ANDREWS ET AL.: "Drug repurposing and human parasitic protozoan diseases", INTERNATIONAL JOURNAL FOR PARASITOLOGY, DRUGS AND DRUG RESISTANCE, vol. 4, 24 March 2014 (2014-03-24), pages 95 - 111 *
GARCIA ET AL.: "Treatment with Benznidazole during the Chronic Phase of Experimental Chagas' Disease Decreases Cardiac Alterations", ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, vol. 49, no. 4, 1 April 2005 (2005-04-01), pages 1521 - 1528 *
PLANER ET AL.: "Synergy Testing of FDA-Approved Drugs Identifies Potent Drug Combinations against Trypanosoma cruzi", PLOS NEGLECTED TROPICAL DISEASES, vol. 8, no. ISS. 7, 17 July 2014 (2014-07-17), pages 1 - 10 *
ROIX ET AL.: "Systematic Repurposing Screening in Xenograft Models Identifies Approved Drugs with Novel Anti-Cancer Activity", PLOS ONE, vol. 9, no. ISS. 8, 6 August 2014 (2014-08-06), pages 1 - 8 *

Also Published As

Publication number Publication date
WO2014186623A2 (en) 2014-11-20

Similar Documents

Publication Publication Date Title
WO2014186623A3 (en) Methods and compositions for the treatment of a chagas disease
WO2015095819A3 (en) Cancer treatment using combinations of erk and raf inhibitors
MX2013011721A (en) Methods for treating conditions associated with masp-2 dependent complement activation.
PH12016501750A1 (en) Human plasma kallikrein inhibitors
EA201491008A1 (en) COMBINATION OF ANTHAGONIST CRTH2 AND PROTONE PUMP INHIBITOR FOR THE TREATMENT OF EOSINOPHIL ESOPHAGITIS
EP2512479A4 (en) Methods and compositions for treating peripheral vascular disease
MX2015012850A (en) Arginine methyltransferase inhibitors and uses thereof.
MX2013005543A (en) Method of treating contrast-induced nephropathy.
WO2014153100A3 (en) Arginine methyltransferase inhibitors and uses thereof
MY164730A (en) Aminoalcohol substituted 2,3-dihydroimidazo[1,2-c]quinazoline derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
MX2008011633A (en) Aminoquinolones as gsk-3 inhibitors.
WO2012050831A3 (en) Combination treatment for dermatological conditions
HK1162502A1 (en) Cyanoaminoquinolones and tetrazoloaminoquinolones as gsk-3 inhibitors gsk-3
MX2021010297A (en) Human plasma kallikrein inhibitors.
EA201590820A1 (en) DERIVATIVES 4-CARBOXAMIDOISOINDOLONONE AS PARP-1 SELECTIVE INHIBITORS
PH12015500012A1 (en) Benzodioxole derivative and preparation method and use thereof
UA109793C2 (en) Arylsulphonamide derivatives for the treatment of disorders of the central nervous system
EA201491026A1 (en) DERIVATIVES 3-PHENYLISOHINOLIN-1 (2H) -ONE AS PARP-1 INHIBITORS
WO2010107791A3 (en) Pyrazinoisoquinoline compounds
WO2014047288A3 (en) Transglutaminase tg2 inhibitors, pharmaceutical compositions, and methods of use thereof
MY198083A (en) Bicyclic pyridine compound
PH12015500282A1 (en) N-acylhydrazone derivatives for selective t cell inhibitor and anti-lymphoid malignancy drug
WO2011156900A3 (en) Compounds, compositions and methods for treatment of multiple sclerosis
TWI839690B (en) Use of a pharmaceutical combination for the treatment of melanoma
WO2014023869A3 (en) Therapeutic use of cd44 inhibitor agents against human acute lymphoblastic leukaemia (all)

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14798002

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 14798002

Country of ref document: EP

Kind code of ref document: A2